{"id":1663,"date":"2012-10-03T11:07:51","date_gmt":"2012-10-03T15:07:51","guid":{"rendered":"http:\/\/blogs.cdc.gov\/genomics\/?p=1663"},"modified":"2024-04-08T16:10:39","modified_gmt":"2024-04-08T20:10:39","slug":"new-strategies","status":"publish","type":"post","link":"https:\/\/blogs.cdc.gov\/genomics\/2012\/10\/03\/new-strategies\/","title":{"rendered":"New Strategies For Public Health Genomics Beyond Newborn Screening"},"content":{"rendered":"

A Working Meeting and an Action Plan
\nto Save Lives Now<\/h1>\n

Nearly 2 million Americans are affected by one of three genetic conditions with a strong risk of early morbidity and mortality: BRCA 1\/2\u00a0and hereditary breast and ovarian cancer; Lynch syndrome and colorectal\u00a0, endometrial and ovarian cancer; and familial hypercholesterolemia and early cardiovascular events.\u00a0 At present these conditions are poorly identified by the healthcare system but evidence based recommendations are available to prevent disease and improve health<\/a>.<\/p>\n

\"Opening
Opening speaker, Dr. Ursula Bauer Director, NCCDPHP discusses a point later in the day with Dr. Khoury, OPHG Director<\/figcaption><\/figure>\n

On September 7, 2012, eighty experts and stakeholders representing federal, state and local public health agencies, clinicians, key advocates and community leaders came together at CDC\u2019s Roybal headquarters in Atlanta to develop a plan to use evidence based \u201cTier I\u201d<\/a> interventions to reduce morbidity and mortality from these three conditions.\u00a0 The event was organized by the CDC Office of Public Health Genomics (OPHG) with help from the University of Michigan Center for Public Health and Community Genomics, Genetic Alliance, and a multi-disciplinary planning committee. The full meeting report is published on the Genomics Forum website and is available for\u00a0download at\u00a0\u00a0https:\/\/stacks.cdc.gov\/view\/cdc\/24147\/cdc_24147_DS1.pdf<\/a><\/p>\n

The day\u2019s work centered around: reviewing the evidence of effectiveness in implementing available interventions; identifying opportunities, strategies, and models; and identifying the means to achieve success for these new and cost effective public health programs.<\/p>\n

\u00a0<\/a><\/p>\n

\"pyramid\"<\/a>Using the \u201cHealth Impact Pyramid\u201d<\/a> as a guide, participants discussed various steps which could be taken, given challenges and opportunities for improvement. Particular emphasis shpuld be given to actions lower on the pyramid, such as policy changes (for example: coverage\/care for Tier 1 applications). Interventions at this level have more population impact because they change the context to make people\u2019s default decisions healthy.<\/p>\n

Said Deb Duquette MS, CGC of the Michigan Department of Community Health, one of several state representatives present at the event,”Clearly work to inform policy change is critical for Tier 1 programs and has been a major part of our success in Michigan. This was particularly true where healthcare coverage for the USPSTF BRCA 1\/2 recommendation was expanded to seven million people in our state.\u00a0 The public health impact for the dollar is large in the policy area and this model can be applied in many other states.\u201d<\/p>\n

At the end of the day, a public health action plan was assembled to implement these strategies through state public health departments in partnership with health care payers and providers:<\/div>\n
    \n
  1. Incorporate and build on the previous success of state public health genomics programs, in particular by employing \u00a0new policy implementation approaches<\/a>;<\/li>\n
  2. \u00a0Develop and use standardized protocols as a guide for Tier 1 program activities;<\/li>\n
  3. \u00a0Develop and distribute standardized communication materials for Tier 1 applications including educational materials for patients, providers, and public health practitioners;<\/li>\n
  4. \u00a0Develop and use standardized surveillance indicators, such as those for HP2020 <\/a>\u00a0to measure success and integrate synergistically with provider\/payer systems;<\/li>\n
  5. \u00a0Collaborate and share lessons learned with other states and partners such as what is being done with the \u00a0Lynch Syndrome Screening Network<\/a> (LSSN);<\/li>\n
  6. Conduct cascade screening<\/a> (identifying relatives at risk from case patients) pilot projects and consider the scalability and cost effectiveness of broader \u00a0programs that use it ;<\/li>\n
  7. \u00a0Build strong partnerships toward mutual goals which include healthcare payers, healthcare providers, advocacy groups, and other key stakeholders;<\/li>\n
  8. \u00a0Stay abreast of changes in the field as new applications with sufficient evidence for implementation become available.<\/li>\n<\/ol>\n

    To follow up on the event\u2019s success, a \u201cTier 1 Toolkit\u201d is now being developed which will provide the tools and educational resource identified during the event as keys to progress. This resource will be available on CDC\u2019s website before the end of this year, and will help states to overcome the unique challenges\u00a0in this arena, establish key healthcare and payer partnerships, and take action to save lives now using Tier 1 public health genomics applications.<\/p>\n


    \n\"The<\/a> The event\u2019s Patient and Community Perspectives Panel included key\u00a0leaders (from left to right): Katherine Wilemon, Founder and President, the FH (Familial Hypercholesterolemia) Foundation; Sue Friedman, DVM – Executive Director, FORCE (Facing Our Risk of Cancer Empowered); Cristi Radford, MS, CGC – Lynch Syndrome International \/ Moffitt Cancer Center; Rochelle Shoretz, JD – Executive Director, Sharsheret: Your Jewish Community Facing Breast Cancer; Sabrina Ford, PhD – Department of Obstetrics, Gynecology & Reproductive Biology, Michigan State University; and Winona Hollins Hauge, MSW, LCSW – Fred Hutchinson Cancer Center, Governor’s Interagency Council for Health Equity (Washington State), National Community Committee Genomics SPIG\/UW HPRC.<\/p>\n

    \n
    <\/dt>\n
    <\/dd>\n<\/dl>\n

    New Strategies in Public Health Genomics:\u00a0 Actions to Save Lives Now
    \n<\/span><\/strong>Atlanta, Georgia
    \n<\/strong>September 7, 2012<\/strong><\/p>\n\n\n\n\n
    Planning Committee<\/span>:<\/strong><\/td>\nSylvia Au \u2013 Hawaii State Department of HealthScott Bowen \u2013 Centers for Disease Control & PreventionSummer Cox \u2013 Oregon Health AuthorityRebecca Giles \u2013 Utah Department of Health Asthma ProgramKaren Greendale \u2013 Centers for Disease Control & PreventionKatherine Johansen Taber \u2013 The American Medical AssociationJenna McLosky – Michigan Department of Community Health<\/p>\n

    James O’Leary \u2013 Genetic Alliance<\/p>\n

    Patricia Page \u2013 Emory University<\/p>\n

    Joan Scott \u2013 National Coalition for Health Professional Education in Genetics<\/p>\n

    Amy Zlot \u2013 Oregon Health Authority<\/td>\n<\/tr>\n

    Speakers<\/span>:<\/strong><\/td>\nLynch Syndrome speaker 1:<\/strong>
    \nHeather Hampel \u2013 The Ohio State UniversityLynch Syndrome speaker 2:<\/strong>
    \nDebra Duquette \u2013 Michigan Department of Community HealthHereditary Breast and Ovarian Cancer speaker 1:<\/strong>
    \nMark Robson \u2013 Memorial Sloan-Kettering Cancer CenterHereditary Breast and Ovarian Cancer speaker 2:<\/strong>
    \nAmber Roche \u2013 Public Health Seattle & King CountyFamilial Hypercholesterolemia speaker 1:<\/strong>
    \nJames Underberg \u2013 NYU School of Medicine and NYU Center for Prevention of Cardiovascular DiseaseFamilial Hypercholesterolemia speaker 2:<\/strong>
    \nJoan Ware \u2013 National Association of Chronic Disease Directors<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    A Working Meeting and an Action Plan to Save Lives Now Nearly 2 million Americans are affected by one of three genetic conditions with a strong risk of early morbidity and mortality: BRCA 1\/2\u00a0and hereditary breast and ovarian cancer; Lynch syndrome and colorectal\u00a0, endometrial and ovarian cancer; and familial hypercholesterolemia and early cardiovascular events.\u00a0 At<\/p>\n","protected":false},"author":126,"featured_media":1669,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5761,5740,5236,31864],"tags":[5739,5726,31856,170],"_links":{"self":[{"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/posts\/1663"}],"collection":[{"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/users\/126"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/comments?post=1663"}],"version-history":[{"count":131,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/posts\/1663\/revisions"}],"predecessor-version":[{"id":6690,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/posts\/1663\/revisions\/6690"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/media\/1669"}],"wp:attachment":[{"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/media?parent=1663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/categories?post=1663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cdc.gov\/genomics\/wp-json\/wp\/v2\/tags?post=1663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}